Related Experiment Video
Updated: Sep 30, 2025

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
Hemi- and Central Retinal Vein Occlusion Associated with COVID-19 Infection in Young Patients without Known Risk
Noy Ashkenazy1, Nimesh A Patel2, Jayanth Sridhar1
1Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.
Insights
COVID-19 infection may be linked to retinal vein occlusions (RVO) in younger adults. This study found that most patients with RVO following COVID-19 experienced vision improvement after treatment.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Vascular Medicine
Background:
- Coronavirus disease 2019 (COVID-19) is associated with venous thromboembolic events.
- A potential link between COVID-19 and retinal vein occlusion (RVO) warrants investigation.
Purpose of the Study:
- To investigate the association between COVID-19 infection and the occurrence of RVO.
- To raise awareness of potential thromboinflammatory effects of COVID-19 on retinal vasculature.
Main Methods:
- Retrospective, multicenter case series.
- Included patients aged 18-50 with hemi-RVO or central RVO and confirmed COVID-19.
- Excluded patients with hypertension, diabetes, glaucoma, obesity, or hypercoagulable states.
Main Results:
- Twelve eyes of 12 patients (median age 32) with RVO post-COVID-19 were analyzed.
- Median time from COVID-19 diagnosis to symptoms was 6.9 weeks.
- 92% achieved final visual acuity of ≥20/40, with 42% experiencing macular edema treated with anti-VEGF.
Conclusions:
- COVID-19 infection may be associated with RVO in younger individuals.
- While causality isn't proven, heightened thromboinflammation from COVID-19 could increase retinal vascular event risk.
- Most patients showed visual recovery, suggesting potential for favorable outcomes with timely management.
Purpose:
Venous thromboembolic complications have been reported in association with coronavirus disease 2019 (COVID-19) infection. We raised awareness regarding a potential temporal association between COVID-19 infection and retinal vein occlusion (RVO).
Design:
Multicenter, retrospective, nonconsecutive case series.
Subjects:
Patients presenting with hemi-RVO (HRVO) or central RVO (CRVO) between March 2020 and March 2021, with confirmed COVID-19 infection, were included. The exclusion criteria were as follows: age >50 years, hypertension, diabetes, glaucoma, obesity, underlying hypercoagulable states, and those requiring intubation during hospitalization.
Methods:
This was a multicenter, retrospective, nonconsecutive case series including patients presenting with hemi-RVO (HRVO) or central RVO (CRVO) between March 2020 and March 2021, with confirmed COVID-19 infection. The exclusion criteria were as follows: age >50 years, hypertension, diabetes, glaucoma, obesity, underlying hypercoagulable states, and those requiring intubation during hospitalization.
Main Outcome Measures:
Ophthalmic findings, including presenting and final visual acuity (VA), imaging findings, and clinical course.
Results:
Twelve eyes of 12 patients with CRVO (9 of 12) or HRVO (3 of 12) after COVID-19 infection were included. The median age was 32 years (range, 18-50 years). Three patients were hospitalized, but none were intubated. The median time from COVID-19 diagnosis to ophthalmic symptoms was 6.9 weeks. The presenting VA ranged from 20/20 to counting fingers, with over half (7 of 12) having a VA of ≥20/40. OCT revealed macular edema in 42% of the eyes; of these, 80% (4 of 5) were treated with anti-VEGF injections. Ninety-two percent (11 of 12) had partial or complete resolution of ocular findings at final follow-up. Four eyes (33%) had retinal thinning, as determined using OCT, by the end of the study interval. The final VA ranged from 20/20 to 20/60, with 11 of the 12 (92%) eyes achieving a VA of ≥20/40 at a median final follow-up period of 13 weeks (range, 4-52 weeks).
Conclusions:
Although we acknowledge the high seroprevalence of COVID-19 and that a causal relationship cannot be established, we reported this series to raise awareness regarding the potential risk of retinal vascular events due to a heightened thromboinflammatory state associated with COVID-19 infection.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Glaucoma: Overview
Venous Thrombosis I: Introduction
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Photoreceptors and Visual Pathways

